ArticlemedRxiv : the preprint server for health sciences2025
Structural Maintenance of Chromosomes 5/6 complex dysfunction enables tumor mutagenesis.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
4 authors.
Funding
Abstract
The Structural Maintenance of Chromosomes (SMC) 5/6 complex is highly conserved and essential for mammalian development. SMC5/6 dysfunction in cells, model organisms, and patients with germline variants results in genome instability, though the exact function of the complex in genome maintenance remains enigmatic. Despite the importance of SMC5/6 in maintaining genome stability, the prevalence and consequences of somatic inactivation of SMC5/6 in cancer is understudied. Here we report a pan-cancer analysis of SMC5/6 dysfunction in cancer across three large databases. We identified thousands of tumors across all tissue types with copy number alteration and/or small variants in SMC5/6 genes. We found that deleterious variants in SMC5/6, but not copy number alterations, are associated with elevated tumor mutational burden (TMB). Mutagenesis in tumors with SMC5/6 variants was caused by polymerase epsilon (POLE) dysfunction and mismatch repair deficiency (MMRd). Patients in which SMC5/6 gene variants occur in tumor genomes exhibited improved survival relative to patients with non-altered SMC5/6 genes. This survival benefit was explained in part by a superior response to immunotherapy in a cohort of patients with colorectal cancer. Our findings demonstrate that dysfunction of SMC5/6 is predictive of elevated TMB and susceptibility to immunotherapy, indicating that SMC5/6 gene status should be considered in cancer diagnostic studies for prognostic implications and tailored therapeutics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.